The Dose-Response Relationship of Tranexamic Acid
1995/02/01 by Jan C. Horrow, Jan C. Horrow, Daniel F. Van Riper +7 · 26 citations
Medicine · #Blood transfusion and management #Trauma, Hemostasis, Coagulopathy, Resuscitation #Hemostasis and retained surgical items
paper · pdf · doi:10.1097/00000542-199502000-00009
Abstract
BACKGROUND: Prophylactic administration of the antifibrinolytic drug tranexamic acid decreases bleeding and transfusions after cardiac operations. However, the best dose of tranexamic acid for this purpose remains unknown. This study explored the dose-response relationship of tranexamic acid for hemostatic efficacy after cardiac operation. METHODS: In prospective, randomized, double-blinded fashion, 148 patients undergoing cardiac operation with extracorporeal circulation were divided into six groups: a placebo group and five groups receiving tranexamic acid in loading doses before incision (range 2.5 to 40 mg.kg-1) and one-tenth the loading dose hourly for 12 h. The mass of blood collected by chest tubes over 12 h represented blood loss. Allogeneic transfusions within 12 h and within 5 d of surgery were tallied. RESULTS: The six groups presented similar demographics. Patients receiving placebo had increased postoperative D-dimer concentration compared to groups receiving tranexamic acid. Patients receiving at least 10 mg.kg-1 tranexamic acid followed by 1 mg.kg-1.h-1 bled significantly less (365, 344, and 369 g.12 h-1, respectively, for those three groups) compared with patients who received placebo (552 g, P < 0.05). Tranexamic dose did not affect transfusions. Only initial hematocrit affected whether a patient received an allogeneic transfusion within 5 days of operation (odds ratio 2.08 for each 3% absolute decrease in hematocrit). CONCLUSIONS: Prophylactic tranexamic acid, 10 mg.kg-1 followed by 1 mg.kg-1.h-1, decreases bleeding after extracorporeal circulation. Larger doses do not provide additional hemostatic benefit.
Cited by
- Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial
- Tranexamic acid for major spinal surgery. [europepmc]
- The impact of administration of tranexamic acid in reducing the use of red blood cells and other blood products in cardiac surgery. [europepmc]
- Management of bleeding following major trauma: a European guideline. [europepmc]
- Giving tranexamic acid to reduce surgical bleeding in sub-Saharan Africa: an economic evaluation. [europepmc]
- Management of bleeding following major trauma: an updated European guideline. [europepmc]
- The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. [europepmc]
- Tranexamic acid in cardiac surgery: is there a cause for concern? [europepmc]
- Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. [europepmc]
- Safety and effectiveness of two treatment regimes with tranexamic acid to minimize inflammatory response in elective cardiopulmonary bypass patients: a randomized double-blind, dose-dependent, phase IV clinical trial. [europepmc]
- CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. [europepmc]
- HALT-IT--tranexamic acid for the treatment of gastrointestinal bleeding: study protocol for a randomised controlled trial. [europepmc]
- Transfusion practices in trauma. [europepmc]
- Antifibrinolytic Therapy and Perioperative Considerations. [europepmc]
- TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial. [europepmc]
- Efficacy and tolerance of early administration of tranexamic acid in patients with cirrhosis presenting with acute upper gastrointestinal bleeding: a study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (the EXARHOSE study). [europepmc]
- Optimal use of tranexamic acid for total hip arthroplasty: A network meta-analysis. [europepmc]
- Introduction of a standardised protocol, including systematic use of tranexamic acid, for management of severe adult trauma patients in a low-resource setting: the MSF experience from Port-au-Prince, Haiti. [europepmc]
- Reducing perioperative blood loss with antifibrinolytics and antifibrinolytic-like agents for patients undergoing total hip and total knee arthroplasty. [europepmc]
- Comparison of Blood-Conserving and Allogenic Transfusion-Sparing Effects of Antifibrinolytics in Scoliosis Correction Surgery. [europepmc]
- Comparison of the in-vivo effect of two tranexamic acid doses on fibrinolysis parameters in adults undergoing valvular cardiac surgery with cardiopulmonary bypass - a pilot investigation. [europepmc]
- Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression. [europepmc]
- A Systematic Review of Tranexamic Acid in Plastic Surgery: What's New? [europepmc]
- Synthesis and Hemostatic Activity of New Amide Derivatives. [europepmc]
- Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial. [europepmc]
- The effect of tranexamic acid on intraoperative blood loss in patients undergoing brain meningioma resections: Study protocol for a randomized controlled trial. [europepmc]
Related